135 related articles for article (PubMed ID: 23295697)
1. Mucosal protection by phosphatidylcholine.
Stremmel W; Ehehalt R; Staffer S; Stoffels S; Mohr A; Karner M; Braun A
Dig Dis; 2012; 30 Suppl 3():85-91. PubMed ID: 23295697
[TBL] [Abstract][Full Text] [Related]
2. [Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis].
Stremmel W
Z Gastroenterol; 2013 Apr; 51(4):384-9. PubMed ID: 23585269
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis?
Stremmel W; Hanemann A; Ehehalt R; Karner M; Braun A
Dig Dis; 2010; 28(3):490-6. PubMed ID: 20926877
[TBL] [Abstract][Full Text] [Related]
4. Lecithin as a therapeutic agent in ulcerative colitis.
Stremmel W; Gauss A
Dig Dis; 2013; 31(3-4):388-90. PubMed ID: 24246994
[TBL] [Abstract][Full Text] [Related]
5. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis--a review of three clinical trials.
Stremmel W; Hanemann A; Braun A; Stoffels S; Karner M; Fazeli S; Ehehalt R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1623-30. PubMed ID: 21105858
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry.
Ehehalt R; Wagenblast J; Erben G; Lehmann WD; Hinz U; Merle U; Stremmel W
Scand J Gastroenterol; 2004 Aug; 39(8):737-42. PubMed ID: 15513358
[TBL] [Abstract][Full Text] [Related]
7. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis.
Braun A; Treede I; Gotthardt D; Tietje A; Zahn A; Ruhwald R; Schoenfeld U; Welsch T; Kienle P; Erben G; Lehmann WD; Fuellekrug J; Stremmel W; Ehehalt R
Inflamm Bowel Dis; 2009 Nov; 15(11):1705-20. PubMed ID: 19504612
[TBL] [Abstract][Full Text] [Related]
8. Exogenous phosphatidylcholine supplementation improves intestinal barrier defense against Clostridium difficile toxin.
Olson A; Diebel LN; Liberati DM
J Trauma Acute Care Surg; 2014 Oct; 77(4):570-5; discussion 576. PubMed ID: 25250596
[TBL] [Abstract][Full Text] [Related]
9. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation.
Schneider H; Braun A; Füllekrug J; Stremmel W; Ehehalt R
Int J Mol Sci; 2010 Oct; 11(10):4149-64. PubMed ID: 21152327
[TBL] [Abstract][Full Text] [Related]
10. Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation.
Dial EJ; Zayat M; Lopez-Storey M; Tran D; Lichtenberger L
Shock; 2008 Dec; 30(6):729-33. PubMed ID: 18496240
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylcholine as a constituent in the colonic mucosal barrier--physiological and clinical relevance.
Ehehalt R; Braun A; Karner M; Füllekrug J; Stremmel W
Biochim Biophys Acta; 2010 Sep; 1801(9):983-93. PubMed ID: 20595010
[TBL] [Abstract][Full Text] [Related]
12. Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease.
Strugala V; Dettmar PW; Pearson JP
Int J Clin Pract; 2008 May; 62(5):762-9. PubMed ID: 18194279
[TBL] [Abstract][Full Text] [Related]
13. Colonic mucus, smoking and ulcerative colitis.
Pullan RD
Ann R Coll Surg Engl; 1996 Mar; 78(2):85-91. PubMed ID: 8678464
[TBL] [Abstract][Full Text] [Related]
14. Reinforcement of the intestinal mucus layer protects against Clostridium difficile intestinal injury in vitro.
Diebel LN; Liberati DM
J Am Coll Surg; 2014 Sep; 219(3):460-8. PubMed ID: 25067805
[TBL] [Abstract][Full Text] [Related]
15. Genetic Mouse Models with Intestinal-Specific Tight Junction Deletion Resemble an Ulcerative Colitis Phenotype.
Stremmel W; Staffer S; Schneider MJ; Gan-Schreier H; Wannhoff A; Stuhrmann N; Gauss A; Wolburg H; Mahringer A; Swidsinski A; Efferth T
J Crohns Colitis; 2017 Oct; 11(10):1247-1257. PubMed ID: 28575164
[TBL] [Abstract][Full Text] [Related]
16. Intestinal mucus barrier in normal and inflamed colon.
Corazziari ES
J Pediatr Gastroenterol Nutr; 2009 Apr; 48 Suppl 2():S54-5. PubMed ID: 19300126
[TBL] [Abstract][Full Text] [Related]
17. Dietary phosphatidylcholine supplementation attenuates inflammatory mucosal damage in a rat model of experimental colitis.
Kovács T; Varga G; Erces D; Tőkés T; Tiszlavicz L; Ghyczy M; Boros M; Kaszaki J
Shock; 2012 Aug; 38(2):177-85. PubMed ID: 22576006
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylcholine passes through lateral tight junctions for paracellular transport to the apical side of the polarized intestinal tumor cell-line CaCo2.
Stremmel W; Staffer S; Gan-Schreier H; Wannhoff A; Bach M; Gauss A
Biochim Biophys Acta; 2016 Sep; 1861(9 Pt A):1161-1169. PubMed ID: 27365309
[TBL] [Abstract][Full Text] [Related]
19. [Intestinal mucosa protection of muscovite n ulcerative colitis in rats].
Wang LJ; Chen SJ; Si JM
Zhongguo Zhong Yao Za Zhi; 2005 Dec; 30(23):1840-4. PubMed ID: 16499023
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer.
Malecka-Panas E; Kordek R; Biernat W; Tureaud J; Liberski PP; Majumdar AP
Hepatogastroenterology; 1997; 44(14):435-40. PubMed ID: 9164515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
